These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31672401)

  • 21. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.
    Spycher M; Matozan K; Minnig K; Zehnder R; Miescher S; Hoefferer L; Rieben R
    Vox Sang; 2009 Nov; 97(4):348-54. PubMed ID: 19656348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of Protein Corona on Nanoparticle Affects Different Complement Activation Pathways Mediated by C1q.
    Ding T; Sun J
    Pharm Res; 2019 Dec; 37(1):10. PubMed ID: 31872347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
    Gyongyossy-Issa MI; McLeod E; Devine DV
    J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.
    Vachino G; Gelfand JA; Atkins MB; Tamerius JD; Demchak P; Mier JW
    Blood; 1991 Nov; 78(10):2505-13. PubMed ID: 1824247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Off-label use of plastic syringes with silicone oil for intravenous infusion bags of antibodies.
    Kim NA; Hada S; Kim DJ; Choi DH; Jeong SH
    Eur J Pharm Biopharm; 2021 Sep; 166():205-215. PubMed ID: 34237379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.
    Rieben R; Roos A; Muizert Y; Tinguely C; Gerritsen AF; Daha MR
    Blood; 1999 Feb; 93(3):942-51. PubMed ID: 9920844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement activation by cigarette smoke.
    Robbins RA; Nelson KJ; Gossman GL; Koyama S; Rennard SI
    Am J Physiol; 1991 Apr; 260(4 Pt 1):L254-9. PubMed ID: 1902064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil extracellular traps can activate alternative complement pathways.
    Wang H; Wang C; Zhao MH; Chen M
    Clin Exp Immunol; 2015 Sep; 181(3):518-27. PubMed ID: 25963026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introducing the Alba
    Chillon A; Pace A; Zuccato D
    PDA J Pharm Sci Technol; 2018; 72(4):382-392. PubMed ID: 29853611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics.
    Depaz RA; Chevolleau T; Jouffray S; Narwal R; Dimitrova MN
    J Pharm Sci; 2014 May; 103(5):1384-93. PubMed ID: 24643773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Tubing Type, Formulation, and Postpumping Agitation on Nanoparticle and Microparticle Formation in Intravenous Immunoglobulin Solutions Processed With a Peristaltic Filling Pump.
    Her C; Carpenter JF
    J Pharm Sci; 2020 Jan; 109(1):739-749. PubMed ID: 31108051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C4a: An Anaphylatoxin in Name Only.
    Barnum SR
    J Innate Immun; 2015; 7(4):333-9. PubMed ID: 25659340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aliskiren inhibits renin-mediated complement activation.
    Békássy ZD; Kristoffersson AC; Rebetz J; Tati R; Olin AI; Karpman D
    Kidney Int; 2018 Oct; 94(4):689-700. PubMed ID: 29884545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
    Patel AR; Lau D; Liu J
    Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids.
    Wagner JL; Hugli TE
    Anal Biochem; 1984 Jan; 136(1):75-88. PubMed ID: 6711816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compartmental distribution of complement activation products in artificial kidneys.
    Cheung AK; Chenoweth DE; Otsuka D; Henderson LW
    Kidney Int; 1986 Jul; 30(1):74-80. PubMed ID: 3489123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C3, C5, and factor B bind to chitosan without complement activation.
    Marchand C; Bachand J; Périnêt J; Baraghis E; Lamarre M; Rivard GE; De Crescenzo G; Hoemann CD
    J Biomed Mater Res A; 2010 Jun; 93(4):1429-41. PubMed ID: 19927329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.